Engineered vaccine trains immune system to target COVID-19
NCT ID NCT04276896
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests a new vaccine called LV-SMENP, designed to teach the body's immune cells to recognize and attack the COVID-19 virus. The vaccine uses a harmless virus to deliver pieces of the coronavirus into dendritic cells, which then activate T cells to fight infection. The study includes about 100 people with confirmed COVID-19 to see if the vaccine is safe and can improve symptoms or prevent severe pneumonia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LV-SMENP-DC vaccine and antigen-specific CTLs
What this could lead to
If successful, this vaccine could help prevent severe COVID-19 pneumonia and reduce deaths from the infection.
What could go wrong
This is an early-phase trial with only 100 participants, so the vaccine may not prove effective or safe for wider use. Side effects from the vaccine or immune cells are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATHOGEN INFECTION COVID-19 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••